早盘直击｜今日行情关注

Core Viewpoint - The Shanghai Composite Index has broken through previous highs, confirming the onset of a spring market rally, with significant trading volume and a resurgence of market sentiment [1] Group 1: Market Overview - The Shanghai Composite Index reached a new high, indicating a new upward wave in the market, with trading volume exceeding 2.8 trillion [1] - The market is experiencing a spring rally, with a focus on the sustainability of hot sectors and increasing trading volume [1] Group 2: Future Market Outlook - The spring rally is expected to continue into January, driven by the resolution of global uncertainties and the easing of year-end funding tightness [1] - Key themes for the rally include technology growth narratives and rising raw material prices, primarily fueled by the AI industry investment boom [1] Group 3: Hot Sectors - In January, technology and raw material price increases are expected to dominate, with a focus on sectors like commercial aerospace, brain-computer interfaces, low-altitude economy, and semiconductors [2] - The rise in raw material prices is seen as a derivative of technology investments, with opportunities in small metals, energy metals, and new chemical materials [2] - Traditional high-dividend sectors are also noted for potential upside as the annual report season approaches [2] Group 4: Specific Trends and Opportunities - The trend of AI hardware remains strong, with a significant increase in token usage for major AI models, indicating a peak in AI applications by 2026 [2] - The domestic production of robots is expected to grow, expanding from humanoid robots to quadrupedal and functional robots, creating opportunities in sensors, controllers, and dexterous hands [2] - The trend towards semiconductor localization continues, with a focus on semiconductor equipment, wafer manufacturing, materials, and IC design [2] - The demand for new energy materials is rising due to rapid growth in domestic and overseas energy storage needs, with signs of supply shortages and price increases expected to continue through 2026 [2] - The innovative drug sector is entering a recovery phase after four years of adjustment, with positive net profit growth expected to continue into 2026 [2]